Abstract

Reactive oxygen species (ROS) have been extensively studied in the induction of inflammation and tissue damage, especially as it relates to aging. In more recent years, ROS have been implicated in the pathogenesis of autoimmune diseases. Here, ROS accumulation leads to apoptosis and autoantigen structural changes that result in novel specificities. ROS have been implicated not only in the initiation of the autoimmune response but also in its amplification and spreading to novel epitopes, through the unmasking of cryptic determinants. This review will examine the contribution of ROS to the pathogenesis of four organ specific autoimmune diseases (Hashimoto thyroiditis, inflammatory bowel disease, multiple sclerosis, and vitiligo), and compare it to that of a better characterized systemic autoimmune disease (rheumatoid arthritis). It will also discuss tobacco smoking as an environmental factor endowed with both pro-oxidant and anti-oxidant properties, thus capable of differentially modulating the autoimmune response.

Keywords

Reactive oxygen species (ROS) · Oxidative stress · Autoimmunity · Hashimoto thyroiditis · Monoamine oxidase (MAO) · Smoking

Abbreviations

ROS Reactive oxygen species
NADPH Nicotinamide adenine dinucleotide phosphate
NOS Nitric oxide synthase
MAO Monoamine oxidase

Introduction

Reactive oxygen species (ROS), also known as free radicals, were first described by Fenton in 1894 [1] and then studied since the mid 1950s for their involvement in aging and age-related conditions [2]. In more recent years, ROS were shown to play a role in physiological processes [3] (such as the synthesis of thyroid hormones and proliferation of thyroid follicular cells [4]), in cellular signaling as second messengers [5], in the normal response of phagocytes to intracellular pathogens, and in a variety of pathological conditions ranging from sarcopenia [6] to cancer [7].

Oxygen is activated by the addition of electron(s) donated by a variety of substances. This transfer of electrons from a substance (reductant) to another one (oxidant) is called redox reaction, a highly conserved reaction that leads to the production of ROS. There are three major ROS: superoxide anion, hydrogen peroxide, and hydroxyl radical (Fig. 1, boxed).

Addition of one electron to molecular oxygen leads to the production of superoxide anion (O$_2^-$), the precursor of the other two ROS. In fact, superoxide anion can dismutate spontaneously to produce hydrogen peroxide by the
addition of another electron and two protons, or be converted enzymatically by the cytosolic superoxide dismutase 1 and the mitochondrial superoxide dismutase 2 (Fig. 1). Hydrogen peroxide (H$_2$O$_2$), a stable ROS, then diffuses through lipid bilayers or intramembranous aquaporins [8], and likely represents the dominant ROS involved in redox signaling due to its stability. Through the classic Fenton reaction (based on the reduction of transition metals, for example from Fe$^{2+}$ to Fe$^{3+}$), H$_2$O$_2$ is then split into hydroxyl radical (OH)/C1 and a hydroxide ion. Hydroxyl radicals are highly reactive and exist for only a microsecond, resulting in an oxidative damage that localizes to the site where they are produced [9]. Hydroxyl radicals can also be formed directly from superoxide anion in the presence of hydrogen peroxide through the Haber–Weiss reaction (Fig. 1).

Several additional molecules can be produced from the three main ROS described above. For example, H$_2$O$_2$ in the presence of a chloride anion is converted by myeloperoxidase into hypochlorous acid, a species important for destroying pathogens within the phagocytic compartment of immune cells [10]. Superoxide can also react with nitric oxide to produce a highly reactive peroxynitrite species (Fig. 1).

This cellular production of ROS is counterbalanced by the presence of numerous molecular and enzymatic antioxidants. Molecules that work as anti-oxidant include vitamins C, A and E, uric acid, glutathione, pycnogenol, and thioredoxin [11]. Antioxidant enzymes include catalase, thioredoxin reductase, glutathione peroxidase, glutathione reductase, glutathione S-transferase, ascorbate peroxidase, ascorbate reductase, and glucose-6-phosphate dehydrogenase [12]. Catalase neutralizes two hydrogen peroxide equivalents into two waters and one molecular oxygen (Fig. 1). On the other hand, glutathione peroxidase uses glutathione as a reducing agent to generate two water equivalents from one hydrogen peroxide species (Fig. 1). To regenerate the pool of glutathione, glutathione reductase converts nicotinamide adenine dinucleotide phosphate to its oxidized form, return oxidized glutathione into its reduced form [13, 14].

**Cellular sources that produce ROS**

There are three major intracellular sources of ROS: electron leak from the mitochondrial respiratory chain, NADPH oxidases, and uncoupled nitric oxide synthase reactions (Fig. 2). ROS can also be generated by monoamine oxidase, and other oxidases such as xanthine oxidase, lipoxygenases, cyclooxygenases, and monoxygenases.

**Electron leak from the mitochondrial respiratory chain**

Mitochondria generate about 90 % of all ROS [15] during the process of ATP production. This process, called oxidative phosphorylation, is driven by the electron transport chain, which consists of five protein complexes located on the inner mitochondrial membrane (Fig. 2, box). The first four complexes utilize oxygen and high-energy electrons to generate a proton gradient in the intermembrane space. The gradient then provides the energy needed to drive the production of ATP by complex. During cellular stress, electrons leak from the respiratory chain and react with molecular oxygen to generate superoxide anion and the secondary ROS [15], which then leave the mitochondria through the permeability transition pore located on the outer membrane [16].
Complex 1, 2, and 3 are the primary sites for ROS production [17], although other factors such as the ratio of ubiquinol to ubiquinone, the mitochondrial membrane potential, and the proton-motive force may be involved [15]. Complex 1 can reduce oxygen to superoxide on the leaflet facing the mitochondrial matrix, and contains a Q-binding site, a flavin mononucleotide, and multiple iron-sulfur clusters that directly participate in ROS production [15, 18]. Complex 2 can alter its catalytic activity to modulate directionality of the electron transport chain to promote ROS production [19], especially when complex 1 or 3 is impaired [20]. Alternative sources of mitochondrial ROS may result from cytochrome C electron transfer to p66-Shc, which subsequently transfers electrons to oxygen in the intermembrane space to generate both superoxide and hydrogen peroxide [21]. Complex 3 transfers electrons from ubiquinol to cytochrome C and mostly generates ROS at the Q-binding site, which diffuses into both the matrix and intermembrane space [15].

**NADPH oxidase**

Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is a flavocytochrome originally discovered in phagocytes. Its function is to release superoxide or hydrogen peroxide in the phagocytic compartment to neutralize pathogens. NADPH oxidase generates superoxide by the catalytic transfer of high energy electrons from the nicotinamide moiety of NADPH to flavin adenine dinucleotide, and then to molecular oxygen.

Phagocytic NADPH oxidase is an assembly of membrane-bound p22 oxidase (p22<sup>phox</sup>), gp91<sup>phox</sup> catalytic subunit, and at least four other cytosolic subunits: p47<sup>phox</sup>, p40<sup>phox</sup>, p67<sup>phox</sup>, and a small G-protein Rac or p21 Rac [22]. Non-phagocytic NADPH oxidase (abbreviated as Nox) refers to homologues of the catalytic gp91 subunit found in non-phagocytic cells [23]. They have similar structure to the phagocytic NAPDH but different biological functions. They are found in endothelial cells and fibroblasts and respond to pro-inflammatory cytokines such as tumor necrosis factor alpha by enhancing superoxide production [24–27], although less efficiently than the phagocytic form. There are seven Nox isotypes (Nox 1 through 5, dual oxidase 1, and dual oxidase 2), mostly localized to the plasma membrane [28]. They generate ROS on the cytosolic leaflet of the plasma membrane or release them into the extracellular milieu, as Nox-containing vesicles fuse with the plasma membrane during Nox activation [28]. ROS produced in this fashion can in turn inhibit Nox to maintain a low basal oxidative state or upregulate it in a feed-forward mechanism [13, 29, 30]. Nox-derived ROS are involved in apoptosis and fibrosis of various tissues [31].

**Uncoupled nitric oxide synthase reactions**

Nitric oxide synthase (NOS) converts L-arginine into citrulline, using tetra-hydro-biopterin as cofactor, as well as other substrates. This reaction releases nitric oxide (NO) (Fig. 1), an important gas that mediates nitric oxide (NO) production and other functions, such as the immune response against parasites [32]. There are three main types of NOS: neuronal, endothelial, and inducible. If substrates become limiting or unusable, the reaction uncouples.
generating large amounts of superoxide, which then reacts with nitric oxide to generate peroxynitrite [10] (Fig. 1), a substance that negates the important vasodilatory effect of nitric oxide. ROS can damage nitric oxide synthase and induce more ROS production in a feed-forward mechanism fashion, promoting in this case endothelial apoptosis, hyper coagulation, and monocyte adhesion [33].

**Monoamine oxidase**

Monoamine oxidase (MAO) is located on the cytosolic leaflet of the outer membrane of mitochondria and mediates the catabolism of monoamine neurotransmitters. There are two well-characterized isotypes of MAO that differ because of their substrate specificity: MAO-A predominantly catabolizes serotonin and noradrenaline, while MAO-B preferentially deaminates phenylethylamine and benzylamine. Dopamine and tyramine are metabolized similarly by both MAO isoforms. MAO isoforms are expressed in several other tissues besides the nervous system: cardiomyocytes, hepatocytes, duodenal villi, vessels, renal collecting tubules, and Bowman’s capsule [34].

In the pancreatic islets, MAO-B is expressed in beta and alpha cells and negatively regulates insulin secretion [35]. MAO contribute to ROS production mainly through the synthesis of H$_2$O$_2$ [36] (Fig. 2).

Inhibition of MAO, and thus inhibition of neurotransmitter degradation, represented the first pharmacological treatment developed for depression in the early 1950s. More recently, MAO inhibitors are being used in other conditions because of their ability to decrease ROS production. For example, Kalurdercic and colleagues identified MAO-derived hydrogen peroxide as a contributor to cardiac damage in ischemia reperfusion injury, and proposed MAO inhibitors as a treatment for this condition [37]. Recently, MAO-derived ROS have been linked to cardiomyocyte necrosis and heart failure by impairing activation of transcription factor-EC activation and mitochondria clearance by lysosomes [38]. In the field of autoimmunity, it has been shown that the MAO inhibitor phenelzine ameliorates disease outcomes in a mouse model of multiple sclerosis [39]. Furthermore, phenytoin, an anticonvulsant that inhibits norepinephrine release and MAO activity, induces proliferation in cultured melanocytes and has therefore, been proposed as a treatment for vitiligo [40].

**ROS in autoimmune diseases**

The role of ROS in autoimmunity is complex. The traditional view holds that ROS accumulation is detrimental to the autoimmune disease process. Oxidative stress ensues when the production of ROS surpasses the buffering capacity of the endogenous antioxidants [41], leading to oxidation of lipids in the plasma membrane, proteins in cytosol and nucleus, and nucleic acids that overall damage the cells in the organ targeted by autoimmunity. Oxidative stress can also lead to the generation of novel autoantigens and thus exacerbation of the autoimmune response [42]. In keeping with these findings, ROS production has been linked directly to inflammation via the production of TNF-α: Salzano et al. reported that macrophages release an oxioreductase that directly stimulates TNF-α [43]. But more recent studies reveal a regulatory role of ROS where they prevent progression of chronic inflammatory responses (reviewed in [44]).

Two excellent reviews have been published on the role of ROS in systemic autoimmune and inflammatory diseases [45, 46]. We will discuss here the contribution of ROS to four organ-specific autoimmune diseases, comparing it to that reported in rheumatoid arthritis, and use tobacco smoking as an example of an environmental factor that can function both as an oxidant and anti-oxidant.

**ROS and Hashimoto thyroiditis**

As mentioned in the introduction, ROS are fundamental for the normal functioning of the thyroid follicular cell. ROS, however, have also been implicated in the pathogenesis of Hashimoto thyroiditis, in both murine and human models.

The NOD-H$_2$H4 mouse is a congenic strain that develops autoimmune thyroiditis spontaneously but at a low incidence, an incidence that can, however, be significantly increased by addition of iodine to the drinking water [47, 48]. Burek and colleagues showed that thyrocytes isolated from NOD-H$_2$H4 mice produced significantly more H$_2$O$_2$ than control thyrocytes when exposed to iodine [49]. They also associated this increased ROS load with higher expression of intracellular adhesion molecule-1 on thyrocytes [50], and therefore, with greater retention capacity of the lymphocytes that infiltrate the thyroid gland. Incubation with the antioxidant diphenyleneiodium, an inhibitor of NADPH oxidase, reduced ROS generation and adhesion molecule expression in cultured NOD-H$_2$H4 thyrocytes [50]. Kolypetri and Carayanniotis showed that ROS increase the apoptosis of NOD-H$_2$H4 thyrocytes exposed to iodine [51]. Thyroidal accumulation of ROS has also been shown to promote cleavage of thyroglobulin into several fragments, likely exposing the immune system to novel epitopes and thus enhancing the autoimmune response [52]. Finally, increased content of 4-HNE, a toxic product from lipid peroxidation used as a marker of oxidative stress, was found in NOD.H$_2$H4 thyroid glands [53]. Overall, studies in the NOD.H$_2$H4 model suggest that thyroidal accumulation of ROS contributes to the initiation and progression of autoimmune thyroiditis.
Studies in patients with Hashimoto thyroiditis are more limited. Ates and colleagues compared 93 cases with Hashimoto thyroiditis (a third in each of the euthyroid, subclinical hypothyroidism, and overt hypothyroidism subgroups), to 31 healthy controls. They found that oxidative stress parameters in the peripheral blood were higher in cases than controls, particularly in the overt hypothyroidism group [54]. In a smaller study of 35 euthyroid Hashimoto cases and 35 healthy controls, Baser et al. reported that serum oxidant status was higher in cases than controls, and positively correlated with the levels of thyroglobulin antibodies [55]. Finally, Ruggieri et al. analyzed 71 euthyroid Hashimoto thyroiditis cases and 63 healthy controls, reporting that oxidative stress is higher in cases and that thryperoxidase antibodies are the main predictor of the oxidative status independent of thyroid function [56]. Overall, human studies report an increased oxidative status in Hashimoto thyroiditis but do not clarify whether this is the cause or result of thyroid dysfunction.

ROS and inflammatory bowel disease

Increased levels of ROS have been reported throughout the colon of patients with inflammatory bowel disease. The increase is not limited to areas of active inflammation, thus suggesting a role for oxidative stress during the early phases of disease pathogenesis [57]. Interestingly, because of the high rate of depression in inflammatory bowel disease, MAO inhibitors are commonly prescribed in this patient population [58]. In a review of studies examining the effectiveness of antidepressants, the MAO inhibitor phenelzine improved both psychiatric and somatic symptoms of inflammatory bowel disease [59]. In addition, numerous case reports have documented clinical improvement or remission of the bowel inflammation upon usage of phenelzine [59, 60]. The normal colon is the organ that, after the placenta, expresses the highest levels of MAO-A, and it is reasonable to postulate that these levels increase even further upon inflammation. Indeed, Magro and colleagues identified markedly lower levels of monoamines in the mucosa of ulcerative colitis patients, suggesting MAO hyperactivity and consequently increased ROS production [61]. Although no study has directly assessed the link between MAO activity and ROS levels in gut mucosa, or their temporal relationship with bowel inflammation, we suggest that MAO inhibition exerts its beneficial effects in ulcerative colitis by lowering the levels of ROS.

ROS and multiple sclerosis

Given the high levels of oxidative activity found in neurological tissues, it is not surprising that ROS have long been associated with the pathological damage typical of multiple sclerosis [62]. Indeed, several oxidized molecules can potentially be used as diagnostic biomarkers [63]. Increased levels of peroxynitrite are found in active multiple sclerosis lesions [64]. ROS have also been implicated in the dysregulation of the blood–brain barrier, which results in faster disease progression due to increased monocyte infiltration and inflammation [65]. By proteomics, Fiorini and colleagues have shown that patients with the relapsing-remitting form of multiple sclerosis have higher levels of oxidized proteins than healthy controls [66]. Ceruloplasmin, antithrombin III, clusterin, apolipoprotein E, and complement C3, were upregulated in cases; vitamin D-binding protein showed an increasing trend toward oxidation in patients going from remission to relapse. Using a whole-genome microarray approach, Fischer et al. found that several mitochondrial genes involved in inducing oxidative stress were upregulated in multiple sclerosis patients [67]. They also found that microglial cells and astrocytes upregulated the p22 subunit of the Nox2 complex within active pathological lesions. These findings suggest that ROS are involved in early disease stages of multiple sclerosis, when myelin sheaths are still intact but there is lymphocytic infiltration and microglial activation [65, 67].

ROS and vitiligo

In patients with vitiligo the epidermis contains increased levels of ROS, mainly H₂O₂ and peroxynitrite, as well as inadequate antioxidant defenses [68]. This ROS increase originates from several sources, both exogenous (ultraviolet radiations, trauma, stress, infections, malignancies, certain drugs) and endogenous. First, there is an elevated activity of NADPH oxidase and NOS, with secondary increase production of ROS and reactive nitrogen species [69] (Fig. 1). Then, there is an accumulation of tetra-hydrobiopterin, an essential cofactor for the aromatic amino acid hydroxylases and NOS. Increased biopterin levels boost the formation of H₂O₂ and inhibit the function of phenylalanine and tyrosine hydroxylases, thus impairing melanin production in melanocytes and inducing norepinephrine accumulation in keratinocytes [70]. Finally, there is an increased activity of MAO-A, which leads to the accumulation of toxic levels of H₂O₂ [71], and a largely impaired mitochondrial function [72]. Low levels of antioxidants, such as catalase, glutathione peroxidase, glucose-6-phosphate dehydrogenase, superoxide dismutase, and vitamins C and E have been reported in the epidermis and serum of vitiligo patients [73–75]. Recently, Jian and colleagues have shown that the anti-oxidant response element nuclear factor E2 protects melanocytes from H₂O₂ damage through the induction of antioxidant...
genes, such as heme oxygenase-1, and that this pathway is functionally deficient in vitiligo melanocytes, rendering them more susceptible to oxidative stress [76, 77].

Increased skin content of ROS not only directly damages the melanocytes but also induces an autoimmune response against them. In fact, ROS modify the structure of key vitiligo autoantigens such as melan A and tyrosinase, leading to the formation of novel epitopes which then trigger autoreactivity. During the early stages of vitiligo, lipid peroxidation levels, a marker of oxidative stress, have been reported to be increased, whereas melanocyte antibodies appear in later disease stages [72], suggesting that ROS play a role in initiating vitiligo and amplifying the loss of melanocytes.

**ROS and rheumatoid arthritis**

Oxidative stress plays an important role in the pathogenesis of rheumatoid arthritis [78]. Staroń and colleagues analyzed erythrocytes from rheumatoid arthritis cases and healthy controls and reported increased lipid peroxidation, decreased activity of antioxidant enzymes, and decreased sodium–potassium ATPase functions [79]. In the synovial cavity, Mapp et al. have found increased ROS content, leading to the oxidation of immunoglobulins, mainly IgM, recognizing the Fc portion of IgG (so called, rheumatoid factor), lipoproteins, lipids, and hyaluronan [80]. Immunoglobulins damaged by oxidation are more sensitive to non-enzymatic degradation by sugars, primarily at arginine and lysine residues, leading to the formation of advanced glycation end products [78], as it is seen in diabetes mellitus where prolonged hyperglycemia glycoxidates hemoglobin into hemoglobin A1c. Indeed, antibodies to glycoxidized IgG are specifically found in patients with early synovitis [81]. Increased ROS also damage the DNA mismatch repair system, which is defective in rheumatoid arthritis, and the DNA itself, resulting in elevated concentrations of 8-oxo-7-hydro-deoxyguanosine [78]. Further tissue damage originates from ROS produced by monocytes and neutrophils [82]. Neutrophils degranulate in the synovial joint releasing myeloperoxidase that, using chloride and H₂O₂, catalyzes the formation of hypochlorous acid (Fig. 1). Hypochlorous acid is a very strong oxidant: it mainly reacts with methionines and cysteines disrupt protein tertiary structure and activity [83]. In keeping with a pathogenic role of ROS, rheumatoid arthritis patients who improve upon treatment with monoclonal antibodies that block tumor necrosis factor alpha do show reduced plasma levels of ROS [84].

Animal models of rheumatoid arthritis have been used to assess the potential therapeutic benefits of anti-oxidant administration. In the adjuvant-induced rat model of the disease, paeoniflorin significantly improved the arthritic symptoms and increased the pain threshold, changes that were associated with boosted activity of the anti-oxidant enzymes catalase and glutathione peroxidase [85]. In the collagen-induced rat model of arthritis, administration of the antioxidant thymoquinone improved arthritis scoring and bone histopathology while reducing pro-inflammatory cytokines and ROS content [86].

**Tobacco smoke as a modulator of the oxidants/anti-oxidants balance**

Tobacco smoke contains a variety of ROS, reactive nitrogen species, and other compounds that increase the burden of oxidative stress [87]. It is unquestionable that smoking has deleterious effects on human health, most notably related to a higher risk of chronic respiratory diseases [77, 88, 89] and cancer [90, 91]. Intriguingly, however, smoking can also be beneficial in a selected group of conditions, for example in patients with ulcerative colitis [92–95], Hashimoto thyroiditis (see Supplemental Table 1 in [96]), and Parkinson disease [97, 98]. In addition, it is known that small amounts of ROS protect the myocardium from hypoxic damage, in a process termed ischemic preconditioning [99]. It is thus possible that ROS acquired from cigarette smoking precondition organs targeted by autoimmunity by inducing some measures of protection. An excellent review on the varied effect of smoking in autoimmune diseases has been recently published [100]. Here, we will focus on the pro-oxidant and anti-oxidant effects of smoking, using autoimmune thyroiditis as an example.

**Pro-oxidant effects of smoking**

ROS in smoking cause oxidative damage to DNA, as indicated by increased urinary levels of 8-hydroxy-2′-deoxyguanosine [101]. Similarly, bronchoalveolar lavage fluid levels of this molecule positively correlate with smoking status [102]. Smoking also contains reactive nitrogen species [77] and thiocyanate that, despite operating through different mechanisms, also leads to increased oxidation in certain organs. Thiocyanate, in fact, competitively inhibits the uptake of iodine by the sodium-iodide symporter, thus reducing the concentration of iodine inside the thyroid cell and possibly leading to higher oxidative load [103].

Some carcinogens generated during the combustion of tobacco contribute to oxidation. For example, 2-amino-9H-pyrido [2,3-b]indole (abbreviated as AβC) becomes activated in vivo to form N-oxidized metabolites that covalently bind to DNA (DNA adducts) and albumin (albumin adducts), promoting mutations and loss of function [104].

Springer
Normal albumin, the most abundant protein in human serum, normally serves as an anti-oxidant because it scavenges ROS (reactive oxygen species) generated during cell metabolism or introduced from the environment. Albumin adducts loose this protective property.

**Anti-oxidant effects of smoking**

Tobacco leaves contain compounds that inhibit the activity of MAO, and thus reduce the amount of ROS produced by these enzymes. Smokers are known to have lower MAO activity than non-smokers. For example, positron emission tomography brain scans using $^{11}$C-based tracers that bind to catalytically active MAO have demonstrated a reduced MAO activity in smokers [105, 106]. More specifically, $^{[11]}$Clorgyline, a potent and irreversible inhibitor of MAO-A, showed a mean 28% reduction in MAO-A activity (ranging from 22 to 38%) across all cortical and subcortical regions imaged [105]. Similarly, using $^{[11]}$Cbefloxatone, which also binds MAO-A reversibly, there was a 60% average reduction in smokers in cortical regions [106]. Different tracers or earlier scans (within 2 h from the last cigarette smoked) could explain the different percent inhibitions observed in the two studies [107].

What are the compounds in cigarette smoking that inhibit the activity of MAOs? Likely many and their presence is perhaps a reason why smokers have difficulty quitting: MAO inhibition, in fact, could provide a pleasant anti-depressant effect, although no solid data support this hypothesis [108]. Trans–trans-farnesol and 2,3,6-trimethyl-1,4-naphthoquinone specifically inhibit MAO-B [109]; β-carboline alkaloids inhibit MAO-A and MAO-B [106]. Nicotine, the major tobacco alkaloid, could also have MAO inhibitory properties. Recently, it has been in fact shown that nicotine chelates ferrous ion (Fe$^{2+}$) in a concentration-dependent fashion. Since Fe$^{2+}$ can produce OH through the Fenton reaction (Fig. 1), these results support a role for nicotine and related alkaloids as antioxidants [110].

Collectively, these results demonstrate that in the highly complex mixture of chemicals characteristic of tobacco smoke there are compounds that have pro-oxidant, antioxidant, or both kinds of properties. Future studies that examining the oxidation status globally, rather than selectively focusing on oxidative or antioxidant effects, could help unravel the overall role of smoking tobacco with regard to oxidation.

**Conclusions**

The role of ROS in autoimmunity remains complex. ROS accumulation has been implicated both in the initiation and progression of autoimmunity, but is still unclear whether it represents a *bona fide* trigger or a harmless accompaniment. It is, however, intriguing to consider the development of selective ROS inhibitors as a tool that could be used to treat a broad spectrum of autoimmune diseases.

**Acknowledgments** The study was supported by patient donations to the Johns Hopkins Hypophysitis and Autoimmune Disease Research Centers.

**Compliance with ethical standards**

**Conflict of interest** Giulia Di Dalmazi, Jason Hirshberg, Daniel Lyle, Joudedh B. Freij, and Patrizio Caturegli declare that they have no conflict of interest.

**Human and animal rights** This article does not contain any studies with human participants or animals performed by any of the authors.

**Informed consent** This is a review article and therefore, Informed Consent from patients is not necessary.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Fenton HJJ (1894) Oxidation of tartaric acid in presence of iron. J Chem Soc 65:899–910
2. Harman D (1956) Aging: a theory based on free radical and radiation chemistry. J Gerontol 11(3):298–300
3. Droge W (2002) Free radicals in the physiological control of cell function. Physiol Rev 82(1):47–95. doi:10.1152/physrev.00018.2001
4. Poncin S, Van Eeckoudt S, Humbert K, Colin IM, Gerard AC (2010) Oxidative stress: a required condition for thyroid cell proliferation. Am J Pathol 176(5):1355–1363. doi:10.2353/ajpath.2010.090682
5. Wang X, Hai C (2016) Novel insights into redox system and the mechanism of redox regulation. Mol Biol Rep. doi:10.1007/s11033-016-4022-y
6. Jackson MJ (2016) Reactive oxygen species in sarcopenia: should we focus on excess oxidative damage or defective redox signalling? Mol Asp Med. doi:10.1016/j.mam.2016.05.002
7. Panieri E, Santoro MM (2016) ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis 7(6):e2253. doi:10.1038/cddis.2016.105
8. Miller EW, Dickinson BC, Chang CJ (2010) Aquaporin-3 mediates hydrogen peroxide uptake to regulate downstream intracellular signaling. Proc Natl Acad Sci USA 107(36):15681–15686. doi:10.1073/pnas.1005776107
9. Hippieli S, Elstner EF (1999) Transition metal ion-catalyzed oxygen activation during pathogenic processes. FEBS Lett 443(1):1–7
10. Taniyama Y, Griendling KK (2003) Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hyperten- sion 42(6):1075–1081. doi:10.1161/01.hyp.0000100443.09293.4f
27. Griendling KK, Sorescu D, Ushio-Fukai M (2000) NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86(5):494–501

28. Brown DI, Griendling KK (2009) Nox proteins in signal transduction. Free Radic Biol Med 47(9):1239–1253. doi:10.1016/j.freeradbiomed.2009.07.023

29. Li WG, Miller FJ Jr, Zhang HJ, Spitz DR, Oberley LW, Weintraub NL (2001) H2O2(2)-induced O(2) production by a non-phagocytic NAD(P)H oxidase causes oxidant injury. J Biol Chem 276(31):29251–29256. doi:10.1074/jbc.M102124200

30. Kovacic HN, Irani K, Goldschmidt-Clermont PJ (2001) Redox regulation of human Rac1 stability by the proteasome in human aortic endothelial cells. J Biol Chem 276(49):48586–48561. doi:10.1074/jbc.M107925200

31. Maejima Y, Kuroda J, Matsushima S, Ago T, Sadoshima J (2011) Regulation of myocardial growth and death by NADPH oxidase. J Mol Cell Cardiol 50(3):408–416. doi:10.1016/j.yjmcc.2010.12.018

32. Forstermann U, Sessa WC (2012) Nitric oxide synthases: regulation and function. Eur Heart J 33(7):829–837a-d. doi:10.1093/eurheartj/ehr304

33. Dimmelmer S, Zeiher AM (2000) Reactive oxygen species and vascular cell apoptosis in response to angiotensin II and proatherosclerotic factors. Regul Pept 90(1–3):19–25

34. Rodriguez MJ, Saura J, Billett EE, Finch CC, Mahy N (2001) Cellular localization of monoamine oxidase A and B in human tissues outside of the central nervous system. Cell Tissue Res 304(2):215–220

35. Huang YH, Ito A, Arai R (2005) Immunohistochemical localization of monoamine oxidase type B in pancreatic islets of the rat. J Histochem Cytochem Off J Histochem Soc 53(9):1149–1158. doi:10.1369/jhc.5A6658.2005

36. Pizzinat N, Copin N, Vindis C, Parini A, Cambon C (1999) Reactive oxygen species generation in the pulmonary vasculature. Am J Physiol Lung Cell Mol Physiol 284(5):L710–L719. doi:10.1152/ajplung.00149.2002

37. Kaludercic N, Carpi A, Menabo R, Di Lisa F, Paolocci N (2011) Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim Biophys Acta 1813(7):1323–1332. doi:10.1016/j.bbamcr.2010.09.010

38. Santin Y, Sicard P, Vigneron F, Guilbeau-Frugier C, Dutour M, Laiouzou I, Benamou D, Murali A, Paloucci M, Ballotti M, Meneveau C, Paolocci N (2011) Mitochondrial reactive oxygen species production by monoamine oxidases in intact cells. Naunyn Schmiedeberg’s Arch Pharmacol 384(5):428–431

39. Benson CA, Gong W, Tenorio G, Baker GB, Kerr BJ (2013) The MAO inhibitor phenelzine can improve functional outcomes in mice with established clinical signs in experimental autoimmune encephalomyelitis (EAE). Behav Brain Res 252:302–311. doi:10.1016/j.bbr.2013.06.019

40. Namazi MR (2005) Phenyltoin as a novel anti-vitiiligo weapon. J Autoimmune Dis 2:11. doi:10.1186/1740-2557-2-11

41. Sies H (1997) Oxidative stress: oxidants and antioxidants. Exp Physiol 82(2):291–295

42. Xie H, Zhou F, Liu L, Zhu G, Li Q, Li C, Gao T (2016) Vitiligo: how do oxidative stress-induced autoantigens trigger autoimmunity? J Dermatol Sci 81(1):3–9. doi:10.1016/j.jdermsci.2015.09.003

43. Salzano S, Checconi P, Hanschmann EM, Lillig CH, Bowler LD, Chan P, Vaudry D, Mengozzi M, Coppo L, Sacre S, Aikuri KR, Sahaf B, Herzenberg LA, Herzenberg LA, Mullen L, Ghezzi P (2014) Linkage of inflammation and oxidative stress via release of glutathionylated peroxiredoxin-2, which acts as a danger signal. Proc Natl Acad Sci USA 111(33):12157–12162. doi:10.1073/pnas.1401712111

44. Holmdahl R, Sareila O, Olsson LM, Backdahl L, Wing K (2016) Nef1 polymorphism reveals oxidative regulation of autoimmune...
chronic inflammation. Immunol Rev 269(1):228–247. doi:10.1111/imr.12378
45. Ahsan H, Ali A, Ali R (2003) Oxygen free radicals and systemic autoimmunity. Clin Exp Immunol 131(3):398–404
46. Kienhofer D, Boeltz S, Hoffmann MH (2016) Reactive oxygen homeostasis—the balance for preventing autoimmunity. Lupus 25(8):943–954. doi:10.1177/0961203316640019
47. Kolypetri P, King J, Larijani M, Carayanniotis G (2015) Genes and environment as predisposing factors in autoimmunity: acceleration of spontaneous thyroiditis by dietary iodide in NOD. H2(h4) mice. Int Rev Immunol 34(6):522–556. doi:10.3109/08830185.2015.1065828
48. Braley-Mullen H, Yu S (2015) NOD.H-2h4 mice: an important and underutilized animal model of autoimmune thyroiditis and Sjogren’s syndrome. Adv Immunol 126:1–43. doi:10.1016/bs.ai.2014.11.001
49. Burek CL, Rose NR (2008) Autoimmune thyroiditis and ROS. Autoimmun Rev 7(7):530–537. doi:10.1016/j.autrev.2008.04.006
50. Sharma R, Traore K, Trush MA, Rose NR, Burek CL (2008) Oxidative stress and autoimmunity in Hashimoto’s thyroiditis. Endocrine 48(3):916–923. doi:10.1007/s12020-014-0399-3
51. Poncin S, Colin IM, Decallonne B, Clinckspoor I, Many MC, Duthoit C, Estienne V, Giraud A, Durand-Gorde JM, Rasmussen AK, Feldt-Rasmussen U, Carayon P, Ruf J (2001) Hydrogen peroxide-induced production of a 40 kDa immunoreactive thyroglobulin fragment in human thyroid cells: the onset of thyroid autoimmunity? Biochem J 360(Pt 3):557–562
52. Porcino S, Colin IM, Decallonne B, Clinckspoor I, Many MC, Denef JF, Gerard AC (2010) N-acetylcysteine and 15 deoxy-\{delta\}12,14-prostaglandin J2 exert a protective effect against autoimmune thyroid destruction in vivo but not against interleukin-1\{alpha\}/interferon \{gamma\}-induced inhibitory effects in thyrocytes in vitro. Am J Pathol 177(1):219–228. doi:10.2353/ajpath.2010.091253
53. Ahsan H, Yilmaz FM, Ahsan H, Ali A, Ali R (2003) Oxygen free radicals and systemic autoimmunity in Hashimoto’s thyroiditis. Eur J Endocrinol Eur Fed Endocr Soc 149(6):791–799. doi:10.1530/eje-15-0617
54. Baser H, Can U, Baser S, Yerlikaya FH, Aşlan U, Hidayetolu BT (2015) Assessment of oxidative status and its association with thyroid autoantibodies in patients with euthyroid autoimmune thyroiditis. Endocrine 48(3):916–923. doi:10.1007/s12020-014-0399-3
55. ruggeri RM, Vicchio TM, Cristani M, Certo R, Caccuri D, Alibrandi A, Giovinazzo S, Saija A, Campanelli A, Trimarchi F, Gangemi S (2016) Oxidative stress and advanced glycation end products in Hashimoto’s thyroiditis. Thyroid Off J Am Thyroid Assoc 26(4):504–511. doi:10.1089/thy.2015.0592
56. ZHU H, Li YR (2012) Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated experimental and clinical evidence. Exp Biol Med (Maywood, NJ) 237(5):474–480. doi:10.1258/ebm.2011.011358
57. Graff LA, Walker JR, Bernstein CN (2009) Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis 15(7):1105–1118. doi:10.1002/ibd.20873
58. Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ (2006) Antidepressants and inflammatory bowel disease: a systematic review. Clin Pract Epidemiol Ment Health CP EMH 2:24. doi:10.1186/1745-0179-2-24
59. Kast RE (1998) Crohn’s disease remission with phenelzine treatment. Gastroenterology 115(4):1034–1035
60. Magro F, Vieira-Coelho MA, Fraga S, Serrao MP, Veloso FT, Ribeiro T, Soares-da-Silva P (2002) Improved synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. Dig Dis Sci 47(1):216–224
61. Gilgun-Sherki Y, Melamed E, Ofen D (2004) The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 251(3):261–268. doi:10.1007/s00404-004-0348-9
62. Oliveira SR, Kallaur AP, Reiche EM, Kaimen-Maciel DR, Panis LR, Lozovoy MA, Morimoto HK, Maes M, Dichi I, Simao AN (2016) Albumin and protein oxidation are predictors that differentiate relapsing-remitting from progressive clinical forms of multiple sclerosis. Mol Neurobiol. doi:10.1007/s12020-017-0960-z
63. Gonsette RE (2008) Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J Neurol Sci 274(1–2):48–53. doi:10.1016/j.jns.2008.06.029
64. Ortiz GG, Pacheco-Moises FP, Bitzer-Quintero OK, Ramirez-Anguiano AC, Flores-Alvarado LJ, Ramirez-Ramirez V, Macias-Islas MA, Torres-Sanchez ED (2013) Immunology and oxidative stress in multiple sclerosis: clinical and basic approach. Clin Dev Immunol 2013:708659. doi:10.1155/2013/708659
65. Fiorini A, Koudivratiyeva T, Kucay E, Coccia R, Foppoli C, Giorgi A, Schinina ME, Di Domenico F, De Marco F, Perluigi M (2013) Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis. PLoS One 8(6):e65184. doi:10.1371/journal.pone.0065184
66. Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, Dhiman RM, Kallaur AP, Reiche EM, Kaimen-Maciel DR, Panis LR, Lozovoy MA, Morimoto HK, Maes M, Dichi I, Simao AN (2012) NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain J Neurol 135(Pt 3):886–899. doi:10.1093/brain/aww012
67. Schallreuter KU, Moore J, Wood JM, Beazley WD, Gaze DC, Tobin DJ, Marshall HS, Panske A, Panizg E, Hibberts NA (1999) In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. J Invest Dermatol Symp Proc Soc Invest Dermatol Inc Eur Soc Dermatol Res 4(1):91–96
68. Hann SK, Chang JH, Lee HS, Kim SM (2000) The classification of segmental vitiligo on the face. Yonsei Med J 41(2):209–212. doi:10.3349/ymj.2000.41.2.209
69. Schallreuter KU, Wood JM, Ziegler I, Lemke KR, Pittelkow MR, Lindsey NJ, Gutlich M (1994) Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. Biochim Biophys Acta 1226(2):181–192
70. Schallreuter KU, Wood JM, Pittelkow MR, Buttnar G, Swanson N, Korner C, Ehrke C (1996) Increased monoamine oxidase A activity in the epidermis of patients with vitiligo. Arch Dermatol Res 288(1):14–18
71. Laddha NC, Dwivedi M, Mansuri MS, Singh M, Gani AR, Yesola AP, Panchal VN, Khan F, Dave DJ, Patel A, Madhavan SE, Gupta R, Marfatia Z, Marfatia YS, Begum R (2014) Role of oxidative stress and autoimmunity in onset and progression of vitiligo. Exp Dermatol 23(5):352–353. doi:10.1111/exd.12372
72. Schallreuter KU, Wood JM, Berger J (1991) Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 97(6):1081–1085
73. Sravani PV, Babu NK, Gopal KV, Rao GR, Rao AR, Moorthy B, Rao TR (2009) Determination of oxidative stress in vitiligo...
by measuring superoxide dismutase and catalase levels in vitamin-rich and non-vitamin skin. Indian J Dermatol Venereol Leprol 75(3):268–271. doi:10.4103/0079-6323.48427
75. Farahi-Jahromy A, Fallahzadeh MK, Askhanii-Esfahani S, Hamidizadeh N, Ghavipisheh M, Namazi MR (2014) Decreased glucose-6-phosphate dehydrogenase levels in vitiligo patients: further evidence of oxidative stress. Adv Biomed Res 3:34. doi:10.4103/2277-9175.124686
76. Jian Z, Li K, Liu L, Zhang Y, Zhou Z, Li C, Gao T (2011) Heme oxygenase-1 protects human melanocytes from H2O2-induced oxidative stress via the Nrf2-ARE pathway. J Invest Dermatol 131(7):1420–1427. doi:10.1038/jid.2011.56
77. Domej W, Oettl K, Renner W (2014) Oxidative stress and free radicals in COPD–implications and relevance for treatment. Int J Chronic Obstr Pulm Dis 9:1207–1224. doi:10.2147/copd.s51226
78. Hitchon CA, El-Gabalawy HS (2004) Oxidation in rheumatoid arthritis. Arthritis Res Ther 6(6):257–278. doi:10.1186/ar1447
79. Staron A, Makosa G, Koter-Michalak M (2012) Oxidative stress in erythrocytes from patients with rheumatoid arthritis. Rheumatol Int 32(2):331–334. doi:10.1007/s00296-010-1611-2
80. Mapp PI, Grootveld MC, Blake DR (1995) Hypoxia, oxidative stress and rheumatoid arthritis. Br Med Bull 51(2):419–436
81. Newkirk MM, Goldbach-Mansky R, Lee J, Hoxworth J, McCoy A, Yarboro C, Klippel J, El-Gabalawy HS (2003) Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis. Arthritis Res Ther 5(2):R82–R90
82. Ostrakhovitch EA, Afanas’ev IB (2001) Oxidative stress in rheumatoid arthritis leucocytes: suppression by rutin and other antioxidants and chelators. Biochem Pharmacol 62(6):743–746
83. Davies MJ, Hawkins CL, Patterson DL, Rees MD (2008) Mammalian heme peroxidases: from molecular mechanisms to health implications. Antioxid Redox Signal 10(7):1199–1234. doi:10.1089/ars.2007.1927
84. Cacciapaglia F, Anelli MG, Rizzo D, Morelli E, Scioscia C, Mazzotta D, Iannone F, Lapadula G (2015) Influence of TNF-alpha inhibition on oxidative stress of rheumatoid arthritis patients. Reumatismo 67(3):97–102. doi:10.4081/reumatismo.2015.829
85. Jia Z, He J (2016) Paecilomorpha ameliolates rheumatoid arthritis in rat models through oxidative stress, inflammation and cyclooxygenase 2. Exp Ther Med 11(2):655–659. doi:10.3892/etm.2015.3908
86. Umar S, Zargar J, Umar K, Ahmad S, Khatyar CK, Khan HA (2012) Modulation of the oxidative stress and inflammatory cytokine response by thymoquinone in the collagen induced arthritis in Wistar rats. Chem Biol Interact 197(1):40–46. doi:10.1016/j.cbi.2012.03.003
87. van der Toorn M, Rezayat D, Kauffman HF, Bakker SJ, Gans RO, Koeter GH, Choi AM, van Oosterhout AJ, Slobos DJ (2009) Lipid-soluble components in cigarette smoke induce mitochondrial production of reactive oxygen species in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 297(1L):L109–L114. doi:10.1152/ajplung.90461.2008
88. MacNee W (2001) Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol 429(1–3):195–207
89. Repine JE, Bast A, Lankhorst I (1997) Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 156(2 Pt 1):341–357. doi:10.1164/ajrccm.156.2.9611013
90. Florou AN, Gkiozos IC, Tsagouli SK, Soulouits KN, Syrigos KN (2014) Clinical significance of smoking cessation in subjects with cancer: a 30-year review. Respir Care 59(12):1924–1936. doi:10.4187/respcare.02559
91. Sasco AJ, Secretan MB, Straif K (2004) Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung Cancer (Amsterdam, Netherlands) 45(Suppl 2):S3–S9. doi:10.1016/j.lungcan.2004.07.998
92. Boyko EJ, Perera DR, Koepsell TD, Keane EM, Inui TS (1988) Effects of cigarette smoking on the clinical course of ulcerative colitis. Scand J Gastroenterol 23(9):1147–1152
93. Calabrese E, Yanai H, Hustler D, Rubin DT, Hanauer SB (2012) Low-dose smoking resumption in ex-smokers with refractory ulcerative colitis. J Crohn’s Colitis 6(7):756–762. doi:10.1016/j.jcrr.2011.12.010
94. Fraga XF, Vergara M, Medina C, Casellas F, Bermejo B, Malagelada JR (1997) Effects of smoking on the presentation and clinical course of inflammatory bowel disease. Eur J Gastroenterol Hepatol 9(7):683–687
95. Mokbel M, Carbonnel F, Beaumerie L, Gendre JP, Cosnes J (1998) Effect of smoking on the long-term course of ulcerative colitis. Gastroenterol Clin Biol 22(11):858–862
96. Schmelz L, Blevins TC, Aronoff SL, Ozer K, Leffert JD, Goldberg MA, Horowitz BS, Bertenshaw RH, Troya P, Cohen AE, Lanier RK, Ct Wright (2014) Antibiotic supplementation decreases thyroglobulin antibodies in patients with chronic lymphocytic autoimmune (Hashimoto’s) thyroiditis: a randomized controlled clinical trial. J Clin Endocrinol Metab 99(1):E137–E142. doi:10.1210/jc.2013-2951
97. Dorn HF (1959) Tobacco consumption and mortality from cancer and other diseases. Public Health Rep 74(7):581–593
98. Thiriez C, Villafane G, Gropin F, Fenelon G, Remy P, Cesaro P (2011) Can nicotine be used medicinally in Parkinson’s disease? Expert Rev Clin Pharmacol 4(4):429–436. doi:10.1586/ercp.11.27
99. Shao D, Oka S, Brady CD, Haendeler J, Eaton P, Sadoshima J (2015) 2-Amino-9H-pyrido[2,3-b]indole (AalphaC) adducts and thiol oxidation of serum albumin as potential biomarkers of tobacco smoke and autoimmunity: the fire behind the disease. Autoimmun Rev 15(4):354–374. doi:10.1016/j.autrev.2016.01.001
100. Perricone C, Versini M, Ben-Ami D, Gertel S, Watad A, Segel MJ, Ceccarelli F, Conti F, Cantarini L, Bogdanos DP, Antonelli A, Amital H, Valesini G, Shoenefeld Y (2016) Smoke and autoimmunity: the fire behind the disease. Autoimmun Rev 15(4):354–374. doi:10.1016/j.autrev.2016.01.001
101. Tsai CC, Cheng CY, Liu CY, Kao SC, Kau HC, Hsu WM, Wei YH (2009) Oxidative stress in patients with Graves’ ophthalmopathy: relationship between oxidative DNA damage and clinical evolution. Eye (London, England) 23(8):1725–1730. doi:10.1038/eye.2008.310
102. Cao C, Lai T, Li M, Zhou H, Lv D, Deng Z, Ying S, Chen Z, Li W, Shen H (2016) Smoking-promoted oxidative DNA damage response is highly correlated to lung carcinogenesis. Oncotarget. doi:10.18632/oncotarget.7810
103. Steinmaus C, Miller MD, Howd R (2007) Impact of smoking and thiocyanate on perchloride and thyroid hormone associations in the 2001–2002 national health and nutrition examination survey. Environ Health Perspect 115(9):1333–1338. doi:10.1289/ehp.10300
104. Pathak KV, Bellamri M, Wang Y, Langoue S, Turesky RJ, Cobb J (2011) 2-Amino-9H-pyrido[2,3-b]indole (AalphaC) adducts and thiol oxidation of serum albumin as potential biomarkers of tobacco smoke. J Biol Chem 290(26):16304–16318. doi:10.1074/jbc.M111.364659
105. Fowler JS, Volkow ND, Wang GJ, Logan J, Shea C, Alexoff D, MacGregor RR, Schlyer DJ, Zezulkova I, Wolf AP (1996) Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA 93(24):14065–14069
106. Herrera T, Chapparo C (2005) Human monoamine oxidase is inhibited by tobacco smoke: beta-carbolinaldehyde alkaloids act as potent and reversible inhibitors. Biochem Biophys Res Commun 326(2):378–386. doi:10.1016/j.bbrc.2004.11.033
107. Leroy C, Bragulat V, Berlin I, Gregoire MC, Bottlaender M, Roumenov D, Dolle F, Bourgeois S, Pelttilla J, Artiges E,
Martinot JL, Trichard C (2009) Cerebral monoamine oxidase A inhibition in tobacco smokers confirmed with PET and [11C]befloxatone. J Clin Psychopharmacol 29(1):86–88. doi:10.1097/JCP.0b013e31819e98f

108. Hogg RC (2016) Contribution of monoamine oxidase inhibition to tobacco dependence: a review of the evidence. Nicotine Tob Res Off J Soc Res Nicotine Tob 18(5):509–523. doi:10.1093/ntr/ntv245

109. Khalil AA, Davies B, Castagnoli N Jr (2006) Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke. Bioorgan Med Chem 14(10):3392–3398. doi:10.1016/j.bmc.2005.12.057

110. Malczewska-Jaskola K, Jasiewicz B, Mrowczynska L (2016) Nicotine alkaloids as antioxidant and potential protective agents against in vitro oxidative haemolysis. Chem Biol Interact 243:62–71. doi:10.1016/j.cbi.2015.11.030